Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial.

Autio KA, Dreicer R, Anderson J, Garcia JA, Alva A, Hart LL, Milowsky MI, Posadas EM, Ryan CJ, Graf RP, Dittamore R, Schreiber NA, Summa JM, Youssoufian H, Morris MJ, Scher HI.

JAMA Oncol. 2018 Jul 5. doi: 10.1001/jamaoncol.2018.2168. [Epub ahead of print]

PMID:
29978216
2.

Nanomedicines: From Bench to Bedside and Beyond.

Havel H, Finch G, Strode P, Wolfgang M, Zale S, Bobe I, Youssoufian H, Peterson M, Liu M.

AAPS J. 2016 Nov;18(6):1373-1378. Epub 2016 Aug 1. Review.

PMID:
27480318
3.

Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors.

Von Hoff DD, Mita MM, Ramanathan RK, Weiss GJ, Mita AC, LoRusso PM, Burris HA 3rd, Hart LL, Low SC, Parsons DM, Zale SE, Summa JM, Youssoufian H, Sachdev JC.

Clin Cancer Res. 2016 Jul 1;22(13):3157-63. doi: 10.1158/1078-0432.CCR-15-2548. Epub 2016 Feb 4.

4.

Clinical and Translational Results of a Phase II, Randomized Trial of an Anti-IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy.

Gradishar WJ, Yardley DA, Layman R, Sparano JA, Chuang E, Northfelt DW, Schwartz GN, Youssoufian H, Tang S, Novosiadly R, Forest A, Nguyen TS, Cosaert J, Grebennik D, Haluska P.

Clin Cancer Res. 2016 Jan 15;22(2):301-9. doi: 10.1158/1078-0432.CCR-15-0588. Epub 2015 Aug 31.

5.

PMPA for nephroprotection in PSMA-targeted radionuclide therapy of prostate cancer.

Kratochwil C, Giesel FL, Leotta K, Eder M, Hoppe-Tich T, Youssoufian H, Kopka K, Babich JW, Haberkorn U.

J Nucl Med. 2015 Feb;56(2):293-8. doi: 10.2967/jnumed.114.147181. Epub 2015 Jan 22.

6.

Darinaparsin inhibits prostate tumor-initiating cells and Du145 xenografts and is an inhibitor of hedgehog signaling.

Bansal N, Farley NJ, Wu L, Lewis J, Youssoufian H, Bertino JR.

Mol Cancer Ther. 2015 Jan;14(1):23-30. doi: 10.1158/1535-7163.MCT-13-1040. Epub 2014 Nov 7.

7.

A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors.

Chiorean EG, Sweeney C, Youssoufian H, Qin A, Dontabhaktuni A, Loizos N, Nippgen J, Amato R.

Cancer Chemother Pharmacol. 2014 Mar;73(3):595-604. doi: 10.1007/s00280-014-2389-9. Epub 2014 Jan 23.

PMID:
24452395
8.

Getting from the bench to the patient: biotechnology strategies.

Youssoufian H, Lewis J.

Surg Oncol Clin N Am. 2013 Oct;22(4):885-901. doi: 10.1016/j.soc.2013.06.007. Epub 2013 Aug 1. Review.

PMID:
24012404
9.

Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study.

LoRusso PM, Krishnamurthi S, Youssoufian H, Hall N, Fox F, Dontabhaktuni A, Grebennik D, Remick S.

Invest New Drugs. 2014 Apr;32(2):303-11. doi: 10.1007/s10637-013-9998-8. Epub 2013 Aug 1.

PMID:
23903897
10.

An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours.

Schöffski P, Adkins D, Blay JY, Gil T, Elias AD, Rutkowski P, Pennock GK, Youssoufian H, Gelderblom H, Willey R, Grebennik DO.

Eur J Cancer. 2013 Oct;49(15):3219-28. doi: 10.1016/j.ejca.2013.06.010. Epub 2013 Jul 5.

PMID:
23835252
11.

Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer.

Bonomi PD, Mace J, Mandanas RA, Min M, Olsen M, Youssoufian H, Katz TL, Sheth G, Lee HJ.

J Thorac Oncol. 2013 Mar;8(3):338-45. doi: 10.1097/JTO.0b013e318282ded5.

12.

A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer.

Weickhardt A, Doebele R, Oton A, Lettieri J, Maxson D, Reynolds M, Brown A, Jackson MK, Dy G, Adjei A, Fetterly G, Lu X, Franklin W, Varella-Garcia M, Hirsch FR, Wynes MW, Youssoufian H, Adjei A, Camidge DR.

J Thorac Oncol. 2012 Feb;7(2):419-26. doi: 10.1097/JTO.0b013e31823c5b11.

13.

Blockade of insulin-like growth factor type-1 receptor with cixutumumab (IMC-A12): a novel approach to treatment for multiple cancers.

Rowinsky EK, Schwartz JD, Zojwalla N, Youssoufian H, Fox F, Pultar P, Novosyadlyy R, Cosaert J, Ludwig DL.

Curr Drug Targets. 2011 Dec;12(14):2016-33. Review.

PMID:
21777192
14.

A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma.

Ko AH, Youssoufian H, Gurtler J, Dicke K, Kayaleh O, Lenz HJ, Keaton M, Katz T, Ballal S, Rowinsky EK.

Invest New Drugs. 2012 Aug;30(4):1597-606. doi: 10.1007/s10637-011-9691-8. Epub 2011 Jun 1.

PMID:
21629990
15.

Pleiotropic stromal effects of vascular endothelial growth factor receptor 2 antibody therapy in renal cell carcinoma models.

Duignan IJ, Corcoran E, Pennello A, Plym MJ, Amatulli M, Claros N, Iacolina M, Youssoufian H, Witte L, Samakoglu S, Schwartz J, Surguladze D, Tonra JR.

Neoplasia. 2011 Jan;13(1):49-59.

16.
17.
18.

Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer.

Reidy DL, Vakiani E, Fakih MG, Saif MW, Hecht JR, Goodman-Davis N, Hollywood E, Shia J, Schwartz J, Chandrawansa K, Dontabhaktuni A, Youssoufian H, Solit DB, Saltz LB.

J Clin Oncol. 2010 Sep 20;28(27):4240-6. doi: 10.1200/JCO.2010.30.4154. Epub 2010 Aug 16.

19.

A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies.

Kuenen B, Witteveen PO, Ruijter R, Giaccone G, Dontabhaktuni A, Fox F, Katz T, Youssoufian H, Zhu J, Rowinsky EK, Voest EE.

Clin Cancer Res. 2010 Mar 15;16(6):1915-23. doi: 10.1158/1078-0432.CCR-09-2425. Epub 2010 Mar 2. Erratum in: Clin Cancer Res. 2010 Sep 15;16(18):4681. Dosage error in article text.

20.

Anti-transforming growth factor beta receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells.

Zhong Z, Carroll KD, Policarpio D, Osborn C, Gregory M, Bassi R, Jimenez X, Prewett M, Liebisch G, Persaud K, Burtrum D, Wang S, Surguladze D, Ng S, Griffith H, Balderes P, Doody J, Schwartz JD, Youssoufian H, Rowinsky EK, Ludwig DL, Witte L, Zhu Z, Wu Y.

Clin Cancer Res. 2010 Feb 15;16(4):1191-205. doi: 10.1158/1078-0432.CCR-09-1634. Epub 2010 Feb 9.

21.
22.

Targeting FMS-related tyrosine kinase receptor 3 with the human immunoglobulin G1 monoclonal antibody IMC-EB10.

Youssoufian H, Rowinsky EK, Tonra J, Li Y.

Cancer. 2010 Feb 15;116(4 Suppl):1013-7. doi: 10.1002/cncr.24787.

23.

Rationale for the development of IMC-3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet-derived growth factor receptor alpha.

Shah GD, Loizos N, Youssoufian H, Schwartz JD, Rowinsky EK.

Cancer. 2010 Feb 15;116(4 Suppl):1018-26. doi: 10.1002/cncr.24788.

24.

Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.

Spratlin JL, Cohen RB, Eadens M, Gore L, Camidge DR, Diab S, Leong S, O'Bryant C, Chow LQ, Serkova NJ, Meropol NJ, Lewis NL, Chiorean EG, Fox F, Youssoufian H, Rowinsky EK, Eckhardt SG.

J Clin Oncol. 2010 Feb 10;28(5):780-7. doi: 10.1200/JCO.2009.23.7537. Epub 2010 Jan 4.

25.
26.

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.

Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK.

Lancet Oncol. 2010 Jan;11(1):21-8. doi: 10.1016/S1470-2045(09)70311-0. Epub 2009 Nov 10. Erratum in: Lancet Oncol. 2010 Jan;11(1):14.

PMID:
19897418
27.

A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining.

Wierzbicki R, Jonker DJ, Moore MJ, Berry SR, Loehrer PJ, Youssoufian H, Rowinsky EK.

Invest New Drugs. 2011 Feb;29(1):167-74. doi: 10.1007/s10637-009-9341-6. Epub 2009 Oct 15.

PMID:
19830388
28.

IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor.

Rowinsky EK, Youssoufian H, Tonra JR, Solomon P, Burtrum D, Ludwig DL.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5549s-5555s. Review.

29.

Review: monoclonal antibodies to the vascular endothelial growth factor receptor-2 in cancer therapy.

Youssoufian H, Hicklin DJ, Rowinsky EK.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5544s-5548s. Review.

30.

A remedy for biomarker addiction: back to rational anticancer drug development.

Youssoufian H, Rowinsky EK.

Nat Clin Pract Oncol. 2007 May;4(5):264-5. No abstract available.

PMID:
17464335
31.

Defective mitochondrial peroxiredoxin-3 results in sensitivity to oxidative stress in Fanconi anemia.

Mukhopadhyay SS, Leung KS, Hicks MJ, Hastings PJ, Youssoufian H, Plon SE.

J Cell Biol. 2006 Oct 23;175(2):225-35.

32.

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.

Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK.

N Engl J Med. 2006 Feb 9;354(6):567-78.

33.

Oxidative stress as a multiple effector in Fanconi anaemia clinical phenotype.

Pagano G, Degan P, d'Ischia M, Kelly FJ, Nobili B, Pallardó FV, Youssoufian H, Zatterale A.

Eur J Haematol. 2005 Aug;75(2):93-100. Review.

PMID:
16000125
34.

Disruption of ferroportin 1 regulation causes dynamic alterations in iron homeostasis and erythropoiesis in polycythaemia mice.

Mok H, Jelinek J, Pai S, Cattanach BM, Prchal JT, Youssoufian H, Schumacher A.

Development. 2004 Apr;131(8):1859-68.

35.

Fanconi anaemia proteins: major roles in cell protection against oxidative damage.

Pagano G, Youssoufian H.

Bioessays. 2003 Jun;25(6):589-95. Review.

PMID:
12766948
36.

Mechanisms and consequences of somatic mosaicism in humans.

Youssoufian H, Pyeritz RE.

Nat Rev Genet. 2002 Oct;3(10):748-58. Review.

PMID:
12360233
37.

Correction of cross-linker sensitivity of Fanconi anemia group F cells by CD33-mediated protein transfer.

Holmes RK, Harutyunyan K, Shah M, Joenje H, Youssoufian H.

Blood. 2001 Dec 15;98(13):3817-22.

38.

Cell cycle-dependent expression and nucleolar localization of hCAP-H.

Cabello OA, Eliseeva E, He WG, Youssoufian H, Plon SE, Brinkley BR, Belmont JW.

Mol Biol Cell. 2001 Nov;12(11):3527-37.

39.
40.

Fanconi anemia group C protein prevents apoptosis in hematopoietic cells through redox regulation of GSTP1.

Cumming RC, Lightfoot J, Beard K, Youssoufian H, O'Brien PJ, Buchwald M.

Nat Med. 2001 Jul;7(7):814-20.

PMID:
11433346
41.

Fanconi anemia and breast cancer: what's the connection?

Youssoufian H.

Nat Genet. 2001 Apr;27(4):352-3. No abstract available.

PMID:
11279508
42.
43.

Cancer predisposition caused by elevated mitotic recombination in Bloom mice.

Luo G, Santoro IM, McDaniel LD, Nishijima I, Mills M, Youssoufian H, Vogel H, Schultz RA, Bradley A.

Nat Genet. 2000 Dec;26(4):424-9.

PMID:
11101838
44.

Cloning and analysis of the mouse Fanconi anemia group A cDNA and an overlapping penta zinc finger cDNA.

Wong JC, Alon N, Norga K, Kruyt FA, Youssoufian H, Buchwald M.

Genomics. 2000 Aug 1;67(3):273-83.

PMID:
10936049
45.

Analysis of epitope-tagged forms of the dyskeratosis congenital protein (dyskerin): identification of a nuclear localization signal.

Youssoufian H, Gharibyan V, Qatanani M.

Blood Cells Mol Dis. 1999 Oct-Dec;25(5-6):305-9.

PMID:
10744426
46.

Werner helicase expression in human fetal and adult aortas.

Wang L, Evans AE, Ogburn CE, Youssoufian H, Martin GM, Oshima J.

Exp Gerontol. 1999 Dec;34(8):935-41.

PMID:
10673147
47.

Investigation of Fanconi anemia protein interactions by yeast two-hybrid analysis.

Huber PA, Medhurst AL, Youssoufian H, Mathew CG.

Biochem Biophys Res Commun. 2000 Feb 5;268(1):73-7.

PMID:
10652215
48.

Cellular Werner phenotypes in mice expressing a putative dominant-negative human WRN gene.

Wang L, Ogburn CE, Ware CB, Ladiges WC, Youssoufian H, Martin GM, Oshima J.

Genetics. 2000 Jan;154(1):357-62.

50.

Supplemental Content

Loading ...
Support Center